HK1095742A1 - 3-cyano-quinoline derivatives with antiproliferative activity - Google Patents

3-cyano-quinoline derivatives with antiproliferative activity

Info

Publication number
HK1095742A1
HK1095742A1 HK07102919.7A HK07102919A HK1095742A1 HK 1095742 A1 HK1095742 A1 HK 1095742A1 HK 07102919 A HK07102919 A HK 07102919A HK 1095742 A1 HK1095742 A1 HK 1095742A1
Authority
HK
Hong Kong
Prior art keywords
cyano
antiproliferative activity
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
HK07102919.7A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Peter Jacobus Johannes Antonius Buijnsters
Kristof Van Emelen
Werner Constant Johan Embrechts
Timothy Pietro Suren Perera
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1095742(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1095742A1 publication Critical patent/HK1095742A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK07102919.7A 2003-12-18 2007-03-19 3-cyano-quinoline derivatives with antiproliferative activity HK1095742A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP03/51059 2003-12-18
PCT/EP2004/053497 WO2005058318A1 (fr) 2003-12-18 2004-12-15 Derives de 3-cyano-quinoline a activite antiproliferative

Publications (1)

Publication Number Publication Date
HK1095742A1 true HK1095742A1 (en) 2007-05-18

Family

ID=34684508

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102919.7A HK1095742A1 (en) 2003-12-18 2007-03-19 3-cyano-quinoline derivatives with antiproliferative activity

Country Status (23)

Country Link
US (4) US7655642B2 (fr)
EP (1) EP1696914B1 (fr)
JP (1) JP4892353B2 (fr)
KR (1) KR101158440B1 (fr)
CN (1) CN1893944B (fr)
AR (1) AR047060A1 (fr)
AT (1) ATE446750T1 (fr)
AU (1) AU2004298784B2 (fr)
BR (1) BRPI0417609B8 (fr)
CA (1) CA2549728C (fr)
DE (1) DE602004023876D1 (fr)
EA (1) EA200601176A1 (fr)
ES (1) ES2335216T3 (fr)
HK (1) HK1095742A1 (fr)
IL (1) IL176358A (fr)
MX (1) MXPA06007018A (fr)
NO (1) NO337622B1 (fr)
NZ (1) NZ547795A (fr)
SG (1) SG151288A1 (fr)
TW (2) TWI374879B (fr)
UA (1) UA83880C2 (fr)
WO (1) WO2005058318A1 (fr)
ZA (1) ZA200604971B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058318A1 (fr) * 2003-12-18 2005-06-30 Janssen Pharmaceutica N.V. Derives de 3-cyano-quinoline a activite antiproliferative
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US8143255B2 (en) 2005-11-16 2012-03-27 S*Bio Pte Ltd. Heteroalkyl linked pyrimidine derivatives
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
WO2008006884A2 (fr) 2006-07-13 2008-01-17 Janssen Pharmaceutica N.V. DÉRIVÉs de quinazoline de type mtki
EP2123627B1 (fr) * 2007-01-19 2013-11-20 Ube Industries, Ltd. Procédé de production d'amine aromatique ayant un groupe aralkyloxy ou hétéroaralkyloxy
DK2170827T3 (da) * 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
AU2016333987A1 (en) 2015-10-05 2018-05-10 Ny State Psychiatric Institute Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028613A (en) 1990-02-16 1991-07-02 Repligen Corporation Novel pyrroloquinoline alkaloids and methods of use
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
AU763669B2 (en) * 1998-09-29 2003-07-31 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
WO2005058318A1 (fr) * 2003-12-18 2005-06-30 Janssen Pharmaceutica N.V. Derives de 3-cyano-quinoline a activite antiproliferative

Also Published As

Publication number Publication date
NO337622B1 (no) 2016-05-09
ATE446750T1 (de) 2009-11-15
US8778920B2 (en) 2014-07-15
US7655642B2 (en) 2010-02-02
US20080139601A1 (en) 2008-06-12
BRPI0417609A (pt) 2007-04-10
CN1893944B (zh) 2011-07-06
KR20070005560A (ko) 2007-01-10
NO20063324L (no) 2006-07-18
CA2549728C (fr) 2015-07-21
JP2007514711A (ja) 2007-06-07
US9040511B2 (en) 2015-05-26
KR101158440B1 (ko) 2012-07-06
CA2549728A1 (fr) 2005-06-30
NZ547795A (en) 2009-07-31
BRPI0417609B8 (pt) 2021-05-25
TWI374879B (en) 2012-10-21
IL176358A0 (en) 2006-10-05
JP4892353B2 (ja) 2012-03-07
AU2004298784A1 (en) 2005-06-30
UA83880C2 (en) 2008-08-26
TW201132628A (en) 2011-10-01
EP1696914B1 (fr) 2009-10-28
EA200601176A1 (ru) 2006-10-27
TWI389890B (zh) 2013-03-21
EP1696914A1 (fr) 2006-09-06
WO2005058318A1 (fr) 2005-06-30
TW200530187A (en) 2005-09-16
DE602004023876D1 (de) 2009-12-10
US20100069424A1 (en) 2010-03-18
ZA200604971B (en) 2009-05-27
MXPA06007018A (es) 2006-08-31
SG151288A1 (en) 2009-04-30
US20140256948A1 (en) 2014-09-11
AR047060A1 (es) 2006-01-04
US9365517B2 (en) 2016-06-14
AU2004298784B2 (en) 2011-06-09
ES2335216T3 (es) 2010-03-23
CN1893944A (zh) 2007-01-10
BRPI0417609B1 (pt) 2019-02-19
US20130197022A1 (en) 2013-08-01
IL176358A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
ZA200604971B (en) 3-Cyano-quinoline derivatives with antiproliferative activity
PL377514A1 (pl) Pochodne benzoazolilopiperazyny o działaniu antagonistycznym wobec VR1
IL174533A0 (en) Quinazoline derivatives as antiproliferative agents
AP1850A (en) Spiroindolineplperidine derivatives
PL374718A1 (en) Azolidinone-vinyl fused-benzene derivatives
EP1522540A4 (fr) Derives d'azaarene
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
PL375588A1 (en) Pyrimido compounds having antiproliferative activity
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
HK1086842A1 (en) Macrolide-conjugates with anti-inflammatory activity
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
IL166426A0 (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
PL1706373T3 (pl) Pochodne amidoacetonitrylu
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
DE60326941D1 (en) Rs
HK1099649A1 (en) Pesticidal 5-substituted-oxyalkylamino-1-arylpyrazole derivatives 5--
GB0319793D0 (en) Pyridinylmorpholine derivatives
HRP20040318A2 (en) Furochromen derivative with anti-inflammaroty activity
MY144310A (en) 3-cyano-quinoline deriatives with antiproliferative activity
AU2003225764A8 (en) Aza-thioxanthenones with antitumor activity
AU2003224677A8 (en) Aza-benzothiopyranoindazoles with antitumor activity